retatrutide clinical trial duration Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP New Phase 3 retatrutide data

"There has never been a medication or class of medications that has worked for obesity in this way," says Christopher McGowan, MD , an obesity medicine specialist in Cary, North Carolina

SEP-479 oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism Recent Highlights: In May 2025, Septerna signed an exclusive global collaboration with Novo Nordisk worth up to $2.2B to co-develop oral small molecule GLP-1, GIP, and glucagon receptor agonists

Lipid profile changes induced by glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis

The Role of Oxidants and Reactive Nitrogen Species in Irritable Bowel Syndrome: A Potential Etiological Explanation

Jellys favorite Waffle House item is the hash brown bowl: double hash browns, American cheese, scrambled eggs, sausage patties, and onions, peppers, and tomatoes

2019;317:H711H725